Cost–utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy
- 22 October 2003
- journal article
- clinical trial
- Published by Wiley in European Journal of Neurology
- Vol. 10 (6) , 687-694
Abstract
The aim of this study was to provide an incremental cost‐effectiveness analysis comparing intravenous immunoglobulin (IVIg) and prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy. Patients were recruited to a double‐blind randomized crossover trial from nine European centres and received either prednisolone or IVIg during the first 6‐week treatment period on which the economic evaluation was based. A societal perspective was adopted in measuring service use and costs, although the costs of lost employment were not included. The main outcome measure in the economic evaluation was the number of quality adjusted life years (QALYs) gained, with change in a 11‐point disability scale used to measure clinical outcomes. Service use and quality of life data were available for 25 patients. Baseline costs were controlled for using a bootstrapped multiple regression model. The cost difference between the two treatments was estimated to be €3754 over the 6‐week period. Health‐related quality of life, as measured by the EuroQol EQ‐5D instrument, increased more in the IVIg group but the difference was not statistically significant. Using a net‐benefit approach it was shown that the probability of IVIg being cost‐effective in comparison with prednisolone was 0.5 or above (i.e. was more likely to be cost‐effective than cost‐ineffective) only if one QALY was valued at over €250 000. The cost‐effectiveness of IVIg is greatly affected by the price of IVIg and the amount administered. The impact of later side‐effects of prednisolone on long‐term costs and quality of life are likely to reduce the cost per QALY of IVIg treatment.Keywords
All Related Versions
This publication has 23 references indexed in Scilit:
- Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosisCommentary: Evaluating disease modifying treatments in multiple sclerosisBMJ, 2003
- Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathyAnnals of Neurology, 2001
- A BAYESIAN APPROACH TO STOCHASTIC COST-EFFECTIVENESS ANALYSISInternational Journal of Technology Assessment in Health Care, 2001
- Analysis of cost data in randomized trials: an application of the non-parametric bootstrapStatistics in Medicine, 2000
- Effect of Acute -Dopa Pretreatment on Apomorphine-Induced Rotational Behavior in a Rat Model of Parkinson's DiseaseExperimental Neurology, 2000
- Complications of intravenous immune globulin treatment in neurologic diseaseNeurology, 1996
- Aseptic Meningitis Associated with High-Dose Intravenous Immunoglobulin Therapy: Frequency and Risk FactorsAnnals of Internal Medicine, 1994
- High‐dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathyNeurology, 1990
- Plasma Exchange in Chronic Inflammatory Demyelinating PolyradiculoneuropathyNew England Journal of Medicine, 1986
- Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatmentAnnals of Neurology, 1982